Transcode Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Apr 15, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Apr 15, 2025

RNAZ$1.35-12.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2024 and 2023

BALANCE SHEETS


· · December 31, · · December 31,
· · 2024 · · 2023
Assets
Current assets:
Cash	$5,811,064	$2,767,598
Prepaid expenses and other current assets	1,282,274	1,687,846
Total current assets	7,093,338	4,455,444
Property and equipment, net of depreciation	51,574	120,707
Right-of-use asset, net of amortization	37,731	481,694
Security deposit	111,856	111,856
Total assets	$7,294,499	$5,169,701
Liabilities and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable and accrued expenses	$2,708,137	$3,051,259
Deferred grant income	25,408	27,057
Short-term lease liability	38,291	412,280
Total current liabilities	2,771,836	3,490,596
Long-term liabilities:
Warrant Liability - Series C	517,871	—
Warrant Liability - Series D	6,023,526	—
Long-term lease liability	—	38,291
Long-term liabilities	6,541,397	38,291
Total liabilities	9,313,233	3,528,887
Stockholders’ equity:
Preferred stock – $0.0001 par value; 10,000,000 shares authorized at December 31, 2024, and December 31, 2023; -0- shares issued and outstanding at December 31, 2024 and December 31, 2023	—	—
Common stock – $0.0001 par value, 290,000,000 shares authorized at December 31, 2024, and December 31, 2023; 1,029,095 and 19,014 shares issued and outstanding at December 31, 2024, and December 31, 2023, respectively (1)	103	2
Additional paid-in capital	61,183,079	48,057,156
Accumulated deficit	(63,201,916)	(46,416,344)
Total stockholders’ equity (deficit)	(2,018,734)	1,640,814
Total liabilities and stockholders’ equity (deficit)	$7,294,499	$5,169,701

(1)

Since May 2023, the Company has effected three reverse splits of its common stock, either issued and outstanding or held by the Company as treasury stock, (the “Reverse Splits”). None of the Reverse Splits resulted in a change in par value per share, nor did any change the number of authorized shares of common stock. The May 2023 Reverse Split was at a ratio of one share for every 20 shares previously held. The January 2024 Reverse Split was at a ratio of one share for every 40 shares previously held. The December 2024 Reverse Split was at a ratio of one share for every 33 shares previously held. All common stock share and per share data, and exercise price data for applicable common stock equivalents, included in these financial statements have been retroactively adjusted to reflect the Reverse Splits.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.